Effect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cells by Jianming Qiu et al.
RESEARCH Open Access
Effect of a chemical inhibitor of human
phosphatidylethanolamine-binding protein
4 on radiosensitivity of rectal cancer cells
Jianming Qiu1* , Yong Tao1, Guangen Yang1, Kan Xu1, A. Li Lin2 and Liuyu Li2
Abstract
Background: Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a well-established antiapoptosis
molecule in recent years. It has also been demonstrated to be involved in the radioresistance of rectal cancer. The
objective of this study was to determine whether IOI-42, a chemical inhibitor of hPEBP4, could sensitize rectal
cancer cells.
Methods: Rectal cancer cells were treated with IOI-42 alone or in combination with irradiation. Clonogenic survival
assays and tumor volume growth analysis were used, respectively, to study the effect of IOI-42 in vitro and in vivo.
Western blot was adopted to measure the activation of signal pathway.
Results: Clonogenic survival assays showed that IOI-42, combined with irradiation, caused a significant decrease in
colony formation compared with radiation alone, which was associated with the downregulation of Akt activation.
And we also confirmed the effect of IOI-42 in nude mice transplanted with human rectal cancer subcutaneously.
Conclusions: These data suggest that IOI-42 has a potential to enhance the radiosensitivity of rectal cancer cells,
providing a rationale to further investigate the feasibility of combining of IOI-42 with radiation, keeping in mind
that this may result in unexpected toxicities.
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Background
The phosphatidylethanolamine-binding protein (PEBP)
family consists of a number of 21–23-kDa basic pro-
teins, first identified in the bovine brain, with preferen-
tial in vitro affinity for phosphatidylethanolamine, a
component of the cell membrane [1]. A number of func-
tions have been suggested for the mammalian PEBP pro-
teins, including lipid binding and inhibition of serine
proteases [2]. Human phosphatidylethanolamine-binding
protein 4 (hPEBP4) is a novel member of the PEBP family
[3]. A recent study shows that hPEBP4 was an independ-
ent predictive biomarker for the response of rectal cancer
to preoperative radiotherapy [4]. The radioresistance effect
of hPEBP4 has been demonstrated to be associated with
Akt activation [5]. At the very beginning, the study on
hPEBP4 has focused on its antiapoptosis effect [4, 6–9]. A
specific chemical inhibitor of hPEBP4 was also found
through virtual screening, which showed significant antia-
poptosis effect by targeting the conservative PE-binding
domain of the molecule of hPEBP4 [10]. Thus, we specu-
lated that this inhibitor named as IOI-42 may also enhance
the radiosensitivity of rectal cancer. In this study, we evalu-
ated the radiosensitizing effect of IOI-42 both in vitro and
in vivo using the model of rectal cancer cells and nude
mice transplanted with human rectal tumor, respectively.
Methods
Antibody and cells
Antibodies specific to phospho-Akt (Ser473) were from
Cell Signaling Technology (Beverly, MA). LY-294002
was purchased from Sigma-Aldrich (Shanghai, China).
All human rectal cancer cells including HRT18 and HT-
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29 were purchased from the American Type Culture
Collection (Manassas, VA) and maintained in a DMEM
medium (Gibco, USA) supplemented with 10 % (v/v)
fetal calf serum, 4.5 g/l D-glucose, nonessential amino
acids (100 mM each), 100 units/ml penicillin, 100 mg/
ml streptomycin, and 2 mM glutamine at 37 °C in a 5 %
CO2 atmosphere.
Chemical inhibitor of hPEBP4
The structure of IOI-42 was identical as that shown in the
original study [8]. A 10-mM stock solution was prepared
in sterile 0.9 % sodium chloride and stored at 4 °C. In this
study, IOI-42 was used at increasing concentrations from
1 to 10 μM.
Clonogenic survival assay
Exponentially growing rectal cancer cells in monolayer
culture were irradiated in 100-mm Petri dishes using a
250-kVp X-ray (0.61 Gy/min) by single radiation expos-
ure. After exposure to ionizing irradiation, the cells were
harvested for clonogenic survival analysis. Survival after
radiation exposure was defined as the ability of the cells
to maintain their clonogenic capacity and form colonies.
Briefly, after exposure to radiation, cells were trypsi-
nized, counted, and seeded for colony formation in 100-
mm Petri dishes at 500–1000 cells/dish. After incubation
intervals of 21 days, colonies were stained with crystal
violet and counted manually. Colonies consisting of
more than 50 cells were scored, and three replicate
dishes were counted for each treatment.
Experiments were carried out at least three times for
all data points. The experimental results were corrected
for effects induced by the nonirradiated control.
In vivo radiation studies
Male athymic nu/nu mice (4 weeks old) were purchased
from the Experimental Animal Center of Shanghai and
were raised using protocols that had been approved by
the Institutional Animal Care and Use Committee.
Forty-eight mice were randomly divided into four
groups. The mice were injected subcutaneously with 2 ×
106 HRT-18 cells on the right foot pad. When tumors
were approximately 0.5–0.8 cm in the longest diameter,
the mice of four groups were subject to no treatment, ir-
radiation alone, irradiation with IOI-42 intratumoral in-
jection, or IOI-42 alone. Irradiation regimen was as the
following: 2 Gy Cs-radiation source every 3 days for
three times as described before [11]. Tumors were moni-
tored and measured with the formula V = (a × b2)/2
every 3 days. Observation was closed once the average
volume of tumor of any group reached 3.0 cm3. All mice
were executed 33 days after radiation exposure, and
tumor size-time curve as well as the apoptosis of tumor
tissues was analyzed.
Immunohistochemistry analysis of Akt activation and
expression of DNA repair genes
Transplanted human rectal cancer tissues were obtained
from the executed mice. The specimens were fixed with
formalin, embedded in paraffin, and immunostained
with specific antibody using avidin-biotin peroxidase
complex method. Immunoreactivity was evaluated based
on the percent of positive-stained cells.
TUNEL assay
Transplanted tumors from mice were collected and fixed
in 10 % formalin and embedded in paraffin after mice
were excised. After deparaffinization, the tumor samples
were stripped of protein by incubation with 20 mg/ml
proteinase K (Sigma Chemical) for 15 min at room
temperature. TUNEL staining was performed using an
apoptosis in situ detection kit (TaKaRa) according to the
manufacture’s protocols. The frequency of apoptosis was
calculated as an apoptotic index, in which more than
200 positive cells were examined in five random fields of
each group, and TUNEL-positive cells were counted to
calculate the percent of positive cells as the apoptosis
index in situ.
Statistical analysis
Data are expressed as mean values ± SD. Statistical sig-
nificance of differences between groups was tested by
Student’s t test, one-way ANOVA, or chi-square test. A
p value of less than 0.05 was considered significant.
Results
Effects of IOI-42 on clonogenic survival of rectal cancer
cells after irradiation
In order to evaluate the radiosensitizing effect of IOI-42
on rectal cancer in vitro, we examined the effect of IOI-
42 on the clonogenic survival of two rectal cancer cell
lines combined with irradiation. We found that IOI-42
itself did not influence the survival of both HRT-18 and
HT-29 cells. But it significantly enhanced the killing of
rectal cancer cells by irradiation (Fig. 1a, b). Then, we
investigated the concentration dependence inhibition of
colony formation of these cell lines for different concen-
trations of IOI-42. As the concentration of IOI-42
increases, the survival of rectal cancer cells decreased
after irradiation, and the higher the IOI-42 concentra-
tion, the lower the survival of rectal cancer cells (p <
0.05). However, when increased to a concentration of
10 μM, IOI-42 itself significantly reduced the survival of
rectal cancer cells (Fig. 1c, d). So in the following experi-
ments, we chose to study the radiosensitizing effect of
IOI-42 at the concentration of 5 μM.
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IOI-42-mediated radiosensitivity of rectal cancer cells was
Akt dependent
Akt activation has been demonstrated to be essential in
the hPEBP4-mediated radioresistance of rectal cancer
[5], so we explored the role of Akt in the effect of IOI-
42. Firstly, we confirmed the activation of Akt after ir-
radiation, its dramatic inhibition by IOI-42, and its al-
most complete depression by pre-incubation with 20 μM
LY-294002 as well (Fig. 2a). Then, we examined the role
of Akt activation in the radiosensitizing effect of IOI-42.
We found that the effect of IOI-42 was totally abolished
after LY-294002 inhibited activation of Akt for both
HRT-18 and HT-29 cells (Fig. 2b).
IOI-42 promoted the sensitivity of rectal cancers to
irradiation in vivo
To determine whether IOI-42 can also promote the ra-
diosensitivity of colorectal cancer in vivo, we examined
the effect of radiation alone, IOI-42 alone, or in combin-
ation on the growth of subcutaneous HT-29 xenograft
rectal tumors in nude mice (Fig. 3a). We found that
from the 12th day, the tumor volume in the combined
treatment group was significantly smaller than that in
the radiation only group (p < 0.05). And no growth delay
Fig. 1 Effects of IOI-42 on clonogenic survival of rectal cancer cells: a HRT-18 cells. b HT-29 cells with irradiation doses of 4, 8, and 12 Gy, combined with
(or not) 5 μm IOI-42. c HRT-18 cells. d HT-29 cells with different concentrations of IOI-42 combined with 8-Gy radiation
Fig. 2 IOI-42-mediated radiosensitivity of rectal cancer cells was Akt
dependent. a Effect of radiation, IOI-42, and LY-294002 on the activation
of Akt. b LY-294002 abolish the effect of IOI-42 both in HRT-18 and HT-
29 cells. (I is the short form for IOI-42, R is the short form for irradiation)
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was observed in the IOI-42 only group compared with
control (Fig. 3b). We also examined Akt activation of the
tumor tissue with immunohistochemistry, which shows
that IOI-42 significantly compromised irradiation-induced
Akt activation (Fig. 3c). The effect of IOI-42 on the rectal
tumor growth after irradiation was also confirmed by
apoptosis stain in situ (Fig. 3d); the apoptosis index of the
combined group is significantly higher than that of the
group of radiation alone (1.5 vs 0.85, p < 0.05).
Discussion
As the first chemical inhibitor of hPEBP4, IOI-42 has
been demonstrated to be able to block the conservative
PE-binding domain of hPEBP4 and reverse the signal
pathway affected by hPEBP4 overexpression [10]. In the
present study, we proved that IOI-42 could enhance the
radiosensitivity of rectal cancer cells both in vitro and in
vivo through inhibiting hPEBP4-induced Akt activation
after irradiation.
Since hPEBP4 has been shown to be overexpressed in
breast, prostate, and ovarian cancers [3, 6–9], our study
suggested that IOI-42 might also be a potential radiosen-
sitizing agent for all the involved human cancers. There
have been seldom breakthrough in the development of
radiosensitizing agents in recent years. To speed up the
development of radiosensitizing agents, taking advantage
of the differentially expressed gene profile of cancer ra-
ther than just focusing on some classical death signal
pathway might be essential [12–15].
Consistent with previous study with siRNA to silence
hPEBP4 [3], our study confirmed that inhibition of Akt ac-
tivation is pivotal in the radiosensitizing effect of IOI-42.
The upregulation of Akt activation by hPEBP4 was be-
lieved to be reactive oxygen species (ROS)-dependent,
though we did not know the exact signal event downward
of ROS, through which hPEBP4 activated Akt to promote
the radioresistance of rectal cancer [5, 7]. Neither we
know the final effect molecule after Akt activation. One
thing is for sure that targeting the conservative PE-
binding domain of the molecule of hPEBP4 is essential for
IOI-42 in playing its radiosensitizing effect. To address
that problem, we actually compared the expression of
some nucleotide repair genes between irradiation alone
and combination of irradiation with IOI-42 in this study
but found no significant difference for nucleotide repair
genes like FANCG, ERCC1, PMS1/2, BRCA1/2, LIG4, and
Fig. 3 IOI-42 promoted the sensitivity of rectal cancers to irradiation in vivo. a Flow chart for the in vivo radiation experiment. b Growth curve of
transplanted rectal cancer volume for different treatments. c Immunoreactive score for Akt activation in vivo after different treatments (below is
the representative pictures of activated Akt staining of radiation plus IOI-42, radiation alone, and IOI-42 alone). d Representative pictures of TUNEL
assay for different treatments. (I is the short form for IOI-42, R is the short form for irradiation, IRS is the short form for immunoreactive score)
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TP53 [16–20]. So the detailed mechanism of hPEBP4-
induced radioresistance needs further exploration, which
will promote the development of more chemical inhibitors
of hPEBP4 and also the potential application of multi-
targeting chemicals with stronger radiosensitizing effect.
Being a preliminary study of IOI-42 as a radiosensitizing
agent for rectal cancer, we did not examine the side effect
of IOI-42. But we did observe anorexia in some mice sub-
ject to IOI-42 when compared with control. It requires
systematic research to clarify its potential toxic effect
if IOI-42 turned out to be a promising agent to
enhance radiosensitivity.
Conclusions
In summary, this is the very first report on a chemical in-
hibitor of hPEBP4 in promoting the radiosensitivity of
rectal cancer, suggesting IOI-42 may be a potential
radiation-sensitive agent in the clinical treatment of can-
cers. Further work is necessary to demonstrate its efficacy
on other human cancers and also to evaluate its possible
side effect.
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